Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)

April 2021

You'll hear concerns about using an injectable CGRP antagonist (Aimovig, etc) for migraine prevention in patients with CV risks.

Most data suggest that CGRP antagonists have minimal CV impact. But it's mostly short-term and in young patients without CV risks.

Now a recent review of U.S. case reports suggests new-onset or worsening hypertension with Aimovig (erenumab).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

COVID-19 Sort Through Growing Options for COVID-19 Vaccines
Liver Disease Help Manage Dose Adjustments in Liver Disease
HIV & AIDS Be Ready to Answer Questions About the New INSTI HIV Self Test
Bowel Preps Know the Ins and Outs of Bowel Preps
Respiratory & Allergy Digest the Evidence Around Jorveza
Diabetes Ensure Eligible Patients With Diabetes Are on a Statin
Immunosuppressives Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)
Headache Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)
COVID-19 Put Inhaled and Oral COVID-19 Treatments in Perspective